Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.55 |
| ▸ | RAB9A | P51151 | 5/20 | 0.55 |
| ▸ | HPGD | P15428 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.55 |
| ▸ | RELA | Q04206 | 1/20 | 0.55 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 4/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.42 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30478007 | 0.91 | ALDH1A1 (0.58) | ALDH1A1KDM4ERAB9AHPGDMAPT | |
| SCHEMBL7411224 | 0.91 | ALDH1A1 (0.58) | ALDH1A1KDM4ERAB9AHPGDMAPT | |
| SCHEMBL31087243 | 0.85 | KDM4E (0.52) | ALDH1A1KDM4ERAB9AHPGDMAPT | |
| SCHEMBL5890646 | 0.85 | KDM4E (0.52) | ALDH1A1KDM4ERAB9AHPGDMAPT | |
| SCHEMBL25905317 | 0.82 | PTPRC (0.44) | ALDH1A1KDM4ERAB9AHPGDMAPT | |
| SCHEMBL1786738 | 0.81 | HTR7 (0.42) | ALDH1A1KDM4ERAB9AHPGDMAPT | |
| SCHEMBL943905 | 0.81 | HTR7 (0.42) | ALDH1A1KDM4ERAB9AHPGDMAPT | |
| SCHEMBL942945 | 0.81 | HTR7 (0.42) | ALDH1A1KDM4ERAB9AHPGDMAPT | |
| SCHEMBL27460879 | 0.78 | ALDH1A1 (0.47) | ALDH1A1KDM4ERAB9AHPGDMAPT | |
| SCHEMBL28300135 | 0.78 | PDCD1 (0.50) | ALDH1A1KDM4ERAB9AHPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1390026-B1 | TREATMENT OF HPV CAUSED DISEASES | CORNELL RES FOUNDATION INC (US) | 2010-05-05 | — | — | EP | claimed |
| WO-1998050075-A1 | COX-2 INHIBITORS IN COMBINATION WITH NMDA-BLOCKERS FOR TREATING PAIN | ALGOS PHARMACEUTICAL CORPORATION (US) | 1998-11-12 | — | — | WO | claimed |
| EP-1039914-A4 | CYCLOOXYGENASE-2 INHIBITION | CORNELL RES FOUNDATION INC (US) | 2007-06-27 | — | — | EP | disclosed |
| EP-1146789-A4 | TREATING CANCERS ASSOCIATED WITH OVEREXPRESSION OF HER-2/NEU | CORNELL RES FOUNDATION INC (US) | 2007-02-14 | — | — | EP | disclosed |
| US-7041694-B1 | Cyclooxygenase-2 inhibition | CORNELL RESEARCH FOUNDATION, INC. (US) | 2006-05-09 | — | — | US | disclosed |
| US-6936632-B2 | Fused pyrrole compounds, pharmaceutical agents containing the same, and the use thereof | MERCKLE GMBH (DE) | 2005-08-30 | — | — | US | disclosed |
| US-20050096371-A1 | Topical pharmaceutical compositions | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2005-05-05 | — | — | US | disclosed |
| US-20040122002-A1 | Fused pyrrole compounds, pharmaceutical agents containing the same, and the use thereof | MERCKLE GMBH (DE) | 2004-06-24 | — | — | US | disclosed |
| CN-1125044-C | Novel prostaglandin synthase inhibitors | DU PONT MERCK PHARMA (US) | 2003-10-22 | — | — | CN | disclosed |
| US-6486203-B1 | Treating inflammatory diseases of the head and neck with cyclooxygenase-2 inhibitors | CORNELL RESEARCH FOUNDATION, INC. | 2002-11-26 | — | — | US | disclosed |
| US-6403630-B1 | ADMINISTERING A CYCLOOXYGENASE-2 (COX-2) INHIBITOR ALONE OR IN COMBINATION WITH HERCEPTIN? ANTIBODY; USED TO TREAT BREAST CANCER | CORNELL RESEARCH FOUNDATION, INC. | 2002-06-11 | — | — | US | disclosed |
| EP-1039914-A1 | CYCLOOXYGENASE-2 INHIBITION | CORNELL RESEARCH FOUNDATION, INC. (US) | 2000-10-04 | — | — | EP | disclosed |
| WO-2000044225-A1 | TREATING CANCERS ASSOCIATED WITH OVEREXPRESSION OF HER-2/neu | CORNELL RESEARCH FOUNDATION, INC. (US) | 2000-08-03 | — | — | WO | disclosed |
| EP-0783486-B1 | NOVEL PROSTAGLANDIN SYNTHASE INHIBITORS | DU PONT PHARM CO (US) | 1999-10-13 | — | — | EP | disclosed |
| US-5932586-A | ANTIINFLAMMATORY AGENTS; ANTIPYRETICS | DUPONT PHARMACEUTICALS COMPANY (US) | 1999-08-03 | — | — | US | disclosed |
| WO-1999030721-A1 | CYCLOOXYGENASE-2 INHIBITION | CORNELL RESEARCH FOUNDATION, INC. (US) | 1999-06-24 | — | — | WO | disclosed |
| CN-1166167-A | Novel prostaglandin synthase inhibitors | DU PONT MERCK PHARMA (US) | 1997-11-26 | — | — | CN | disclosed |
| EP-0783486-A1 | NOVEL PROSTAGLANDIN SYNTHASE INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-07-16 | — | — | EP | disclosed |
| US-5593994-A | ANTIINFLAMMATORY AGENTS | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-01-14 | — | — | US | disclosed |
| WO-1996010012-A1 | NOVEL PROSTAGLANDIN SYNTHASE INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122002-A1 | Fused pyrrole compounds, pharmaceutical agents containing the same, and the use thereof | PTGS1, PTGS2, PTGER1 | ALDH1A1 302/4885KDM4E 2340/4885RAB9A 3686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.